Hepatitis C Virus Treatment Update | ||||
| Sohag Medical Journal | ||||
| Article 11, Volume 24, Issue 1, January 2020, Page 79-85 PDF (344.32 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2019.18760.1068 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
mona mohammed abd el rhman  1; Ghada Moustafa Moustafa Galal2; Ramy Mamdouh Abd El Hamid3; Safaa Khalaf Abd Allah4
| ||||
| 1tropical medicine and gastroentrology, faculty of medicine, sohag university | ||||
| 2Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University. | ||||
| 3tropical medicine and gastroentrology , sohag university hospital | ||||
| 4tropical medicine and gastroenrology, facultyof medicine, sohag university | ||||
| Abstract | ||||
| Hepatitis C virus (HCV) infection is a worldwide public health problem where anti-HCV prevalence had an estimated 2.8% increase over the last decade, corresponding to more than 185 million infections (3% of the world’s population). Treatment of chronic HCV was based on interferon-α for more than 20 years. Over the last years, the treatment of chronic hepatitis C was evolving rapidly with the development of Interferon-free regimens with direct-acting antiviral agents (DAAs). These regimens induce higher rates of sustained virological response (SVR) and show a favorable safety profile compared with IFN-based treatments. The objective of chronic hepatitis C treatment is to achieve SVR which is defined as the absence of viral replication at 12 or 24 weeks after treatment completion. SVR reduces morbidity and mortality and is equivalent in most cases to cure the HCV infection. When considering a patient for HCV therapy, three important pieces of information are needed to guide the treatment plan for all patients: genotype, prior treatment history, and stage of liver disease | ||||
| Keywords | ||||
| Chronic hepatitis C; DAAs; treatment monitoring | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 203 PDF Download: 520 |
||||
